Feldmann and Maini discovered tumor necrosis factor-alpha as an effective therapeutic target for rheumatoid arthritis and other chronic inflammatory conditions. Their research led to the development of several anti-TNF drugs, transforming treatment for people diagnosed with chronic inflammatory conditions.
A study found that doripenem treatment reduced hospital length of stay and time on mechanical ventilation for patients with ventilator-associated pneumonia. Clinical cure rates were similar to those treated with imipenem-cilastatin.
Feldmann and Maini were selected for their role in the discovery of TNF-alpha as a therapeutic target for rheumatoid arthritis. Their pioneering work led to the development of anti-TNF drugs, transforming treatment for chronic inflammatory conditions.
Researchers at J&JPRD have discovered the biological basis of cold temperature sensation in mice, suggesting TRPM8 modulation could play an important role in certain types of cold-induced pain. This finding may lead to innovative treatments for patients with chronic sensitivity and pain caused by cold.
The Dr. Paul Janssen Award for Biomedical Research honors scientists whose work has the potential to transform human health. This year's award includes a $100,000 cash prize and will be selected by an independent committee chaired by Dr. Solomon Snyder.
Researchers at Johnson & Johnson Pharmaceutical Research & Development have discovered a new molecular mechanism underlying neuropathic pain, which may lead to the development of new treatments. The research focuses on specific types of ion channels called 'pacemaker channels' that initiate constant pain signals to the brain.
The Dr. Paul Janssen Award for Biomedical Research aims to recognize and reward innovative contributions to human health, as identified by a six-member international selection committee. The first Award will be presented in September 2006, with a $100,000 prize and global recognition for the recipient.
R207910, a novel diarylquinoline compound, has demonstrated effectiveness in clearing infection from lungs of mice and reducing bacterial load by 50%. The drug's unique mechanism of action targeting ATP synthase makes it active against drug-resistant strains of TB.